Dental Literature Watch · Trial · Implants

Local Minocycline Adds Short-Term Benefit in Non-Surgical Peri-Implantitis

3of 5Changes some calls
Adjunctive use of locally delivered 2% minocycline in the nonsurgical treatment of peri-implantitis: a multicenter randomized placebo-controlled trial. J Dent 2026;172:106761 · 48 randomised, 46 analysed, single-blind, multicentre

TL;DR

The study

DesignMulticentre, randomised, single-blind, placebo-controlled trial
Sample48 randomised; 46 in per-protocol analysis (22 test, 24 control) after two withdrawals
InterventionSubgingival debridement + 2% minocycline HCl ointment at baseline, weeks 1, 2, 3
Follow-up12 weeks
ClinicalLower adjusted probing depth, less bleeding on probing in the test group
MicrobiologyLower selected pathogens at 8 weeks (p < 0.05); inconsistent at 12 weeks
Patient-reportedLess swelling at 3 weeks; no difference in quality of life

💎 Insight — what this means chairside

The honest framing is delay, not cure
Better pocket depths and less bleeding at three months in a disease measured in years of bone loss is a soft-tissue result.
It may buy time or improve conditions before surgery; it is not shown to change the trajectory of the implant.
The microbiological effect faded between weeks 8 and 12
That is the pattern you would expect from a locally delivered antibiotic without a change in the underlying biofilm environment.
It argues against thinking of this as a durable microbiological reset.
Patients did not feel a difference
Quality of life did not differ, despite the clinical numbers moving.
Worth saying out loud when you are proposing an extra four visits and an extra cost.

⚠️ The catch

Forty-six patients, twelve weeks, single-blind
Small, short, and only single-blinded, in a condition whose outcomes are measured in radiographic bone level over years.
The authors explicitly warn against drawing structural conclusions from the radiographs.
Four appointments in three weeks
Baseline plus weeks 1, 2 and 3 is a demanding protocol for a modest, short-lived benefit.
Adherence in ordinary practice will not look like adherence in a trial.
Antibiotic use for a soft-tissue endpoint
Repeated local antibiotic application to achieve a bleeding-on-probing improvement deserves the same stewardship scrutiny as any other antibiotic decision.

⚡ Bottom line

🧪 Questions

Tap an answer — instant grade, deciding line, and the trap.

A 61-year-old has peri-implantitis at a lower molar implant with 6 mm probing depths, bleeding on probing, suppuration, and 3 mm of radiographic bone loss. You plan non-surgical debridement. Based on the 2026 multicentre trial, what can you accurately tell the patient about adding local 2% minocycline?

Deciding line: the trial found better adjusted probing depths and less bleeding at 12 weeks while the authors explicitly cautioned that the follow-up was too short to support conclusions about structural stability. Trap: promising avoided surgery is the engineered trap because it is what the patient wants to hear and what a soft-tissue improvement can be mistaken for; the quality-of-life option inverts a specifically negative finding, since patient-reported outcomes did not differ.